Showing posts with label Drug. Show all posts
Showing posts with label Drug. Show all posts

Wednesday, August 30, 2017

NEW DRUG DELIVERY CAPSULE MAY REPLACE INJECTIONS


Given a choice, most patients would prefer to take a drug orally instead of getting an injection. Unfortunately, many drugs, especially those made from large proteins, cannot be given as a pill because they get broken down in the stomach before they can be absorbed.


To help overcome that obstacle, researchers at MIT and Massachusetts General Hospital (MGH) have devised a novel drug capsule coated with tiny needles that can inject drugs directly into the lining of the stomach after the capsule is swallowed. In animal studies, the team found that the capsule delivered insulin more efficiently than injection under the skin, and there were no harmful side effects as the capsule passed through the digestive system.
"This could be a way that the patient can circumvent the need to have an infusion or subcutaneous administration of a drug," says Giovanni Traverso, a research fellow at MIT's Koch Institute for Integrative Cancer Research, a gastroenterologist at MGH, and one of the lead authors of the paper, which appears in the Journal of Pharmaceutical Sciences.
Although the researchers tested their capsule with insulin, they anticipate that it would be most useful for delivering biopharmaceuticals such as antibodies, which are used to treat cancer and autoimmune disorders like arthritis and Crohn's disease. This class of drugs, known as "biologics," also includes vaccines, recombinant DNA, and RNA.
"The large size of these biologic drugs makes them nonabsorbable. And before they even would be absorbed, they're degraded in your GI tract by acids and enzymes that just eat up the molecules and make them inactive," says Carl Schoellhammer, a graduate student in chemical engineering and a lead author of the paper.
Safe and effective delivery
Scientists have tried designing microparticles and nanoparticles that can deliver biologics, but such particles are expensive to produce and require a new version to be engineered for each drug.
Schoellhammer, Traverso, and their colleagues set out to design a capsule that would serve as a platform for the delivery of a wide range of therapeutics, prevent degradation of the drugs, and inject the payload directly into the lining of the GI tract. Their prototype acrylic capsule, 2 centimeters long and 1 centimeter in diameter, includes a reservoir for the drug and is coated with hollow, stainless steel needles about 5 millimeters long.
Previous studies of accidental ingestion of sharp objects in human patients have suggested that it could be safe to swallow a capsule coated with short needles. Because there are no pain receptors in the GI tract, patients would not feel any pain from the drug injection.
To test whether this type of capsule could allow safe and effective drug delivery, the researchers tested it in pigs, with insulin as the drug payload. It took more than a week for the capsules to move through the entire digestive tract, and the researchers found no traces of tissue damage, supporting the potential safety of this novel approach.
They also found that the microneedles successfully injected insulin into the lining of the stomach, small intestine, and colon, causing the animals' blood glucose levels to drop. This reduction in blood glucose was faster and larger than the drop seen when the same amount of glucose was given by subcutaneous injection.
"The kinetics are much better, and much faster-onset, than those seen with traditional under-the-skin administration," Traverso says. "For molecules that are particularly difficult to absorb, this would be a way of actually administering them at much higher efficiency."
"This is a very interesting approach," says Samir Mitragotri, a professor of chemical engineering at the University of California at Santa Barbara who was not involved in the research. "Oral delivery of drugs is a major challenge, especially for protein drugs. There is tremendous motivation on various fronts for finding other ways to deliver drugs without using the standard needle and syringe."
Further optimization
This approach could also be used to administer vaccines that normally have to be injected, the researchers say.
The team now plans to modify the capsule so that peristalsis, or contractions of the digestive tract, would slowly squeeze the drug out of the capsule as it travels through the tract. They are also working on capsules with needles made of degradable polymers and sugar that would break off and become embedded in the gut lining, where they would slowly disintegrate and release the drug. This would further minimize any safety concern.


Friday, August 18, 2017

Neuropathy Drug Developments


Finally; real evidence that work is being done in developing new drugs to control neuropathic pain. This long article from pharmalicensing.com (see link below) lists the newest developments and current trials, which hopefully will result in real progress very soon. Much of it won't mean much to the casual reader because of the technical nature of how the chemicals work on the pain signals but keep the drug company names in mind and maybe also a few of the proposed drug names as well. At worst it can be used as a reference point for later; at best it is a refreshing and objective look at what's happening behind the scenes.

Novel Treatments in the Pipeline for Neuropathic Pain
By Gail Schechter, Ph.D.

Characterized by sensations of burning, numbness, and tingling, neuropathic pain is debilitating and difficult to treat; it afflicts more than 5 million persons in the U.S., most patients are unsuccessfully treated, and the cost in lost productivity exceeds $100 billion annually.

Neuropathic pain has multiple etiologies, including metabolic disease, infectious disease, mechanical trauma, central nervous system disorders, toxic agents, compression injuries, and malignant conditions. Specific conditions commonly associated with neuropathic pain include: diabetes, postherpetic neuralgia (shingles), HIV/AIDS, cancer/chemotherapy, alcoholism, trigeminal neuralgia (tic douloreux), fibromyalgia, complex regional pain syndrome, phantom limb pain, carpal tunnel syndrome, back pain, multiple sclerosis, spinal cord injury, and stroke.

For most of the past 20 years, pharmacological treatment has depended primarily on a handful of medications, including old-fashioned tricyclic antidepressants, topical lidocaine and capsaicin patches, narcotics such as oxycontin, the painkiller tramadol, and the widely prescribed gabapentin (Neurontin), originally developed as an anti-seizure medication that modulates calcium influx and GABA transmission.

Big Pharma Provides Pain Relief
Pfizer has turned gabapentin into a $3 billion per year blockbuster medication (not without some bumps) and has recently launched its follow-on medication, pregabalin (Lyrica), fondly known as "super Neurontin." Studies indicate a superior therapeutic index for pregabalin compared to gabapentin. Launched in 2004 in Europe and the U.S., pregabalin was approved by the FDA to treat neuropathic pain associated with diabetic peripheral neuropathy and post-herpetic neuropathy, as well as adjunct treatment for partial seizures. In addition to the analgesic and anticonvulsant indications, it is likely that an anxiolytic indication will be approved in the near future.

Lilly's duloxetine (Cymbalta) also was launched in 2004. As a member of the new generation of antidepressants, duloxetine is a combined serotonin and norepinephrine reuptake inhibitor (SNRi). In addition to its approved indication for depression, it received an additional indication for pain management of neuropathic pain associated with diabetic peripheral neuropathy.

Emerging Therapeutic Targets for Neuropathic Pain
The recent BIO Emerging Company Investor Forum in San Francisco in October showcased more than 200 promising new companies, and it was clear that pain was a burning topic. Company presentations underscored major themes in current pain therapeutics, including: re-emergence of the N-methyl-D-aspartate (NMDA) receptor complex as a suspect of interest; NMDA receptor subtype-specific targets; increased understanding of physiological mechanisms of action; improved drug side effects profiles; better animal models to transition from preclinical to clinical studies; enhanced therapeutic index in humans; emphasis on oral formulations; and novel delivery techniques. Highlights from selected companies focused on pain, mainly neuropathic, illustrate the range of treatment candidates working their way through the pain pipeline.

New Tricks for Old Drugs
A resurgence of interest in NMDA receptors is evident in current pain research. New and improved versions of NMDA receptor antagonists, receptor subtype targets such as gycine, and ion channel modulators have been revived and refined.

Anavir Pharmaceuticals
Anavir focuses on the NMDA receptor as a prime target for the control of neuropathic pain. Excessive activation of the NMDA receptor has been implicated in many diseases, and pharmacological agents that attenuate NMDA receptor activity have been shown to be neuroprotective.

Anavir is developing Neurodex, dextromethorphan in combination with an enzyme inhibitor to block the rapid metabolism of dextromethorphan and maintain elevated blood levels. The rationale for using dextromethorphan to treat neuropathic pain is that it is a potent antagonist of the NMDA receptor. The use of low dose quindine sulfate, an established medication for cardiac arrhythmia, blocks enzyme activity responsible for the rapid degradation of dextromethorphan and sustains elevated blood levels thought to be effective in treating neurological disorders.

Neurodex currently is being tested for the indication of neuropathic pain. Avanir has completed a Phase II trial in patients with diabetic neuropathy. Treatment was well-tolerated and significantly decreased pain intensity. Avanir currently is discussing the Phase III protocol with FDA. Neurodex is also in Phase III clinical trials for uncontrolled laughter or tearfulness, called pseudobulbar affect, occurring in patients with amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's disease, and stroke.

GB Therapeutics Ltd.
GB Therapeutics is targeting the NMDA glutamate receptor recognized for its role in pain and memory. The glutamate antagonist GT 3381 licensed from Chiesi showed good pain relief and a superior safety profile in humans.

Touted as the first new treatment in the third-generation oral NMDA modulators, GT 3381 currently is in Phase II clinical trials as a first-line therapy for neuropathic pain. The company also is developing GT 1061 as a neuroprotective agent to slow the progression of memory and cognitive deficits in Alzheimer's disease.

VistaGen Therapeutics, Inc.
VistaGen is developing a drug targeting epilepsy and neuropathic pain. VistaGen's lead drug candidate AV-101 is an NMDA receptor antagonist entering clinical development. This drug addresses the limitations of previous NMDA receptor antagonists by providing a high therapeutic index, i.e., potent efficacy and minimal adverse side effects. AV-101, L-4-chlorokynurenine, is a novel orally available prodrug (7-chlorokynurenic acid) that is preferentially converted to a potent glycine receptor antagonist at the site of neural damage, where it protects neurons from excitotoxic cell death. The company expects to initiate its AV-101 clinical program for epilepsy and neuropathic pain in early 2006.

The company's second drug candidate, AV-102, modulates neural pathways essential for memory and cognitive function and has therapeutic applications for mental decline associated with disorders of aging. The company also has a unique drug discovery program based on the use of clinically predictive in vitro embryonic stem cells to identify a new generation of drug candidates to treat central nervous system disorders.

Evotec Neurosciences GmbH
Evotec is developing an NMDA receptor NR2B subtype selective antagonist as a neuroprotective agent for neuropathic pain and central nervous system disorders including Parkinson's disease, Alzheimer's disease, stroke, and traumatic brain injury. Previous efforts to develop less selective NMDA antagonists have been plagued by a narrow therapeutic index and delicate balance between clinical benefits and side effects.

The NR2B receptor is forebrain specific and appears to have an improved side effect profile and wider therapeutic index. Its oral availability and lack of off-target responses show promise in animal models. As the company's lead compound, it is anticipated that it will enter into Phase I clinical trials in mid-2005.

Neuromed Technologies, Inc.
Neuromed is the only company in the world with a sole focus on developing calcium channel drugs. Using proprietary screening systems, Neuromed has identified a selective N-type calcium channel blocker with analgesic effects on severe chronic pain. Proof-of-principle for pursuing a peptide that blocks the N-type calcium channel is based on the drug ziconotide (Prialt) that effectively treats severe chronic pain but must be administered intrathecally (directly into the fluid surrounding the spinal cord through a surgically implanted catheter). Ziconotide, a synthetic equivalent of a naturally occurring conopeptide found in a marine snail known as Conus magus, selectively blocks calcium channels on the nerves that ordinarily transmit pain signals to the brain.

Of great importance is the oral and intravenous bioavailability of Neuromed's small molecule drug and its potential to deliver pain relief with minimal side effects. The company's lead candidate drug for chronic pain, NMED-160, is in a Phase I double-blind, randomized, placebo-controlled clinical trial designed to evaluate the drug's safety, tolerability, and pharmacokinetics in healthy individuals. Neuromed also has pipeline programs in anxiety, epilepsy, and cardiovascular disease.

International WEX Technologies, Inc.
Wex's lead product is Tectin for the initial indication of cancer pain and possibly other broad pain indications in the future. The sodium channel blocker, which acts to block pain signals, is derived from the pufferfish toxin, tetrodotoxin (TTX).

Phase II clinical trial results demonstrated that Tectin could relieve pain in refractory cancer pain patients. A recently initiated pivotal Phase IIb/III trial in 25 treatment centers is a randomized, placebo-controlled study in patients with moderate-to-severe cancer pain that is inadequately controlled by existing medication. Tectin is administered via intramuscular injection. The study results are expected in 2005.

ACADIA Pharmaceuticals
ACADIA is developing a class of small molecule agents that activate G-protein coupled receptors (GPCRs) implicated in pain. The two new receptor targets, NPFF and MrG, play a pharmacologically relevant role in pain signaling. The GCPRs appear to have potent, subtype-selective activity. The chemistries were initially found through ACADIA's chemical-genomics technology in which the company is systemically screening members of the GPCR family.

The new targets for pain expand the drug discovery efforts in pain therapeutics, including ACP-102 that targets a GPCR receptor and a preclinical development program targeting muscarinic receptors. The company is in clinical trials for ACP-103 and ACP-104 as adjunctive treatment of schizophrenia and Parkinson's disease.

Pain Therapeutics, Inc.
Pain Therapeutics is developing Oxytrex to treat severe chronic pain. Oxytrex is a unique oral painkiller that combines oxycodone plus ultra low-dose naltrexone to preferentially inhibit an excitatory effect of opioid receptors. This excitatory effect is believed to counteract analgesia and cause tolerance. Its inhibition enhances pain relief and minimizes opioid tolerance.

The company currently is conducting pivotal studies in patients with severe chronic low-back pain (first Phase III) and osteoarthritic pain (second Phase III) to compare the safety and efficacy of Oxytrex against the same total daily dose of oxycodone or placebo. Future research will be directed at the indication of neuropathic pain.

Pharmos
Pharmos' chemical library and list of lead preclinical drug candidates comprise two chemically distinct cannabinoid platforms, the dextrocannabinoid class of compounds and a separate class of cannabinoids showing selectivity toward CB2 receptor binding (PRS 375). Pharmos has completed preclinical/toxicological testing and is ready to move into clinical studies with PRS 375 for pain.

Currently, Pharmos is focusing its resources on its first neuroprotective product, dexanabinol, a non-psychotropic dextrocannabinoid currently undergoing Phase III clinical trials as a treatment for traumatic brain injury and Phase II testing as a preventative agent against post-surgical (CABG) cognitive impairment.

Dov Pharmaceuticals, Inc.
Dov's lead candidate is bicifadine, a chemically distinct molecule with a unique profile of pharmacological activity. It enhances and prolongs the actions of serotonin and norepinephrine by inhibiting the transport proteins that terminate their physiological actions, similar to the mechanism of action of duloxetine. Preclinical studies and clinical trials indicate that these actions may account for the analgesic properties of bicifadine in chronic pain conditions including neuropathic pain.

To date, bicifadine has been tested in 1,555 patients in a number of Phase I and II clinical trials using both immediate- and controlled-release formulations. Bicifadine demonstrated a statistically significant reduction in pain, in some cases comparable to or better than positive controls such as codeine. Phase III clinical trials are planned soon.

XenoPort, Inc.
XenoPort is focused on developing products that harness the body's intrinsic transport systems to improve the oral absorption, distribution, and pharmacokinetics of drugs. The company applies an integrated technology platform--consisting of transporter genomics, assay technology, and proprietary chemistries--to engineer drug molecules for active transport. XenoPort currently is applying its technology to off-patent drugs to provide new, patentable compounds with improved medicinal properties.

XenoPort is in the process of creating new patentable Transported Prodrugs. The company recently initiated two Phase II clinical trials with XB13512, XenoPort's proprietary experimental Transported Prodrug of gabapentin, as a potential treatment for post-herpetic neuralgia and restless legs syndrome.

AlgoRx
AlgoRx is focused on building a diversified portfolio of pharmaceutical products to treat pain. ALGRX 4975 is an injectable capsaicin product for localized, severe, intractable pain. A single administration is expected to provide analgesia for up to several months. Because ALGRX 4975 is injected directly into the painful tissue, it is anticipated to have much greater efficacy than low dose topical capsaicin that is currently available. Alternatively, during surgical procedures, it may be instilled into the surgical wound or onto the cut surfaces of skin, muscle, or bone. The company is pursuing multiple indications for ALGRX 4975: musculoskeletal pain (including osteoarthritis of the knee and tendonitis); post-surgical pain; and post-trauma neuropathic pain. ALGRX 4975 is currently in Phase II clinical development.

A second product in development is ALGRX 3268 (PowderJect(R) Dermal Lidocaine), a needle free, local dermal anesthetic providing analgesia within one minute. It is currently in Phase II clinical testing in children to reduce the pain associated with needlesticks for venipuncture or intravenous cannulations.

NeurogesX, Inc.
NeurogesX is taking a topical approach to treating neuropathic pain of peripheral origin. The company is developing a localized, high-concentration capsaicin dermal patch. The local anesthetic effect results from activation of the transient receptor potential vanilloid 1 (TRPV1) receptor (formerly vanilloid receptor 1 or VR1), a ligand-gated ion channel activated by agonists such as capsaicin. When capsaicin activates TRPV1, calcium enters the cell and pain signals are initiated. When TRPV1 is continuously activated through prolonged exposure to an agonist, excessive calcium enters the cell, initiating processes that result in long-term yet reversible impairment of nociceptor function. This is the proposed mechanism by which NGX-4010 delivers long-term relief to patients with neuropathic pain.

The lead candidate, NGX-4010, provides application of a pure, high-concentration form of synthetic capsaicin, known as trans-capsaicin, directly to the site of pain via a rapid-delivery dermal application system. This potential product is currently being studied in Phase III trials in postherpetic neuralgia and neuropathic pain related to HIV-associated neuropathy. Phase II trials are also ongoing for patients with neuropathic pain related to peripheral diabetic neuropathy.

Future Opportunities
Neuropathic and other chronic pain treatments still face formidable challenges. Increased efficacy, safety, onset of action, and continual day/night relief are desired, but as yet unattained, properties. It is likely that we will next see "me too" drugs following in the large footsteps of the anticonvulsants and antidepressants. The emerging compounds in the pipeline are innovative therapeutic candidates, but they still have a long way to go, and it is too early to predict their future.

http://pharmalicensing.com/public/articles/view/1101203436_41a307ec2804b

How Drug Companies Need Their Patents


Today's post from burrillreport.com (see link below) is interesting because it shows us how drug companies are dependent on their patents for profits. In this case, the makers of Cymbalta (a common drug for the treatment of neuropathic symptoms), Ely Lilly have just lost their patent-exclusivity for Cymbalta and are therefore preparing for a big drop in revenue as other companies move in with alternatives to the drug. More competition is nearly always good news for the patient as it leads to greater choice and generally cheaper prices but there is another side to the story in that companies then have less revenue to invest in new research for newer drugs. It's how the pharmaceutical market works and considering their profit margins, we must be pleased when patents run out and alternatives become available. That said, neuropathy patients are still looking for the big breakthrough new drugs and that requires huge research funds, which are often generated by sales while current drugs are under patent. 

Eli Lilly Still Plans on Meeting 2014 Goals Company faces challenges, but is banking on new approvals and cost cutting.
DANIEL S. LEVINE The Burrill Report  October 03, 2013

“To reach its goals, Lilly says it is banking on targeted growth initiatives and the late-stage drugs in its pipeline.”

Eli Lilly told investors that despite the loss of revenue due to patent expirations for key drugs, it still plans on meeting its goals of generating at least $20 billion in revenue and $3 billion in profit for next year, returning to revenue growth and improving margins after that.

But to do so will be “challenging,” according to Lilly CFO Derica Rice, who noted that devaluation of the Yen and slower market growth in emerging market countries have diminished the company’s near-term expectations for sales growth. Rice says the company is finding appropriate ways to achieve its goals and will take additional actions to achieve its 2014 net income and operating cash flow targets through cutting expenses.

The comments came during a meeting with the investment community held at the company’s global headquarters in Indianapolis.

To reach its goals, Lilly says it is banking on targeted growth initiatives and the late-stage drugs in its pipeline. The company expects to launch several new drugs in 2014 with seven regulatory submissions for four different drugs made in 2013. This includes two drugs for type 2 diabetes and a drug for gastric cancer. The company also said it will make stock repurchases totaling $5 billion over time.

Lilly’s top-selling product, Cymbalta, for the treatment of major depressive disorder and general anxiety disorder, and pain associated with diabetic neuropathy, fibromyalgia and other chronic pain disorders lost patent exclusivity this year. Global sales of the drug accounted for roughly 25 percent of the company’s revenue in the last quarter, and generic selective serotonin and norepinephrine reuptake inhibitors on the market are predicted to reduce Lilly’s 2014 global revenue by 20 percent.

The company says its strategy to focus on development of innovative medicines has produced the strongest pipeline in its 137-year history, with 13 experimental drugs in late-stage clinical testing or in regulatory review and 26 more in mid-stage trials. That’s five times the number of candidates in mid-to-late-stage development than the company had in 2004.

“We’ve undertaken extensive efforts to transform our company to address the challenge of patent expirations and the demands of patients and payers for greater value from medicine,” says John Lechleiter, CEO of Lilly. “Today, we’re seeing our strategy bear fruit, backed by clinical data that strengthens our confidence in our innovation-based strategy and in our ability to return to growth.”


http://www.burrillreport.com/article-lilly_still_plans_on_meeting_2014_goals.html

Wednesday, August 16, 2017

COMMON DIABETES DRUG CAN REDUCE BAD CHOLESTEROL


A common diabetes drug Metformin can also help lower “bad” cholesterol that is known for promoting cardiovascular diseases by hardening the arteries, significant research has found.
“The findings suggest that Metformin might indeed have an additional beneficial effect with regards to cardiovascular diseases among the diabetes patients”, said study first author Dr Tao Xu from Helmholtz Zentrum Minchen, the German research centre for environment health in Neuherberg.
Along with the team from the German Diabetes Centre (DDZ) in Dusseldorf, Dr Tu and colleagues analysed more than 1,800 blood samples of participants.
Using a comprehensive approach, the scientists investigated metabolic products (metabolites) as well as genetics of these participants.
They found that the administration of Metformin in patients suffering from Type 2 Diabetes led to a change in metabolite levels.
According to the authors, this was associated with a significantly decreased level of LDL or “bad” cholesterol.
The researchers speculate that Metformin intake affects the levels of LDL cholesterol, leading to a down-regulation of specific genes.
“This is also supported by the fact that three lipid metabolites are decreased after taking the diabetes drug. Presumably, this is the mechanism how the production of ‘LDL’ cholesterol is repressed by Metformin,” explained
Dr Rui Wang-Sattler from the institute of epidemiology II of the Helmholtz Zentrum Minchen.
“Until now the exact mechanism is unclear. Thus, we want to continue our contribution to its decryption”, added co-study author Dr Stefan Brandmaier in a paper published in the journal Diabetes Care.
Metformin is the oldest and most frequently used oral anti-diabetes drug.
It affects blood fat levels via AMPK signalling pathway. The AMP activated protein kinase (AMPK) is an enzyme that determines the energy status of the cell.

In case, the energy status is low, AMPK stops energy consuming processes like the synthesis of cholesterol or fatty acids.

Saturday, August 12, 2017

Neurontin gabapentin For Neuropathy Drug Interactions


Today's post from neurontin-gabapentin.com (see link below) concerns one of the most commonly prescribed drugs to treat neuropathic symptoms and that is neurontin (gabapentin). What many people fail to realise is that side effects from neurontin mostly don't come from the drug itself but from the interactions it has with other medications. Many people use combinations of drugs to treat various concurrent ailments but it's important to check their interactions and not underestimate the damage they can do. Strictly speaking, your doctor should be keeping a careful eye on all your meds but that requires careful record-keeping and honesty on the part of the patient. If you're concerned that neurontin is producing strange results, please consult your doctor or specialist. Drugs.com is an excellent site for checking your medication interactions.
 
Neurontin interaction with other medication
 

Neurontin has the potential to interact with other drugs. It is found to react with alcohol. It also interacts with antacids, hydrocodone, naproxen and morphine. Neurontin when used in combination with the above mentioned drugs has negative influences. There are many other drugs that Neurontin has interactions. They include the herbal medicines, vitamins and other drugs that your doctor prescribes. So it is very essential that you keep your doctor prescribing Neurontin informed about the other medications you are currently under.

It is known there are nearly about 420 drugs that interact with Neurontin. However, the prime interacting drugs boil down to 5. The number of drugs with minor interaction number to 27. Let us discuss about the prime interacting drugs in brief. The chemical names that could be listed are propoxyphene, caffeine with aspirin and propoxyphene, levomethadyl acetate, sodium oxybate and acetaminophen with propoxyphene.

Neurontin influences the Central Nervous System to perform its desired purpose of anti-depressant or anti-convulsant. This drug when used in combination with propoxyphene influences the respiratory system of the consumer. When propoxyphene is misused, either alone or in combination with other CNS related drugs, it can prove to be fatal as it enhances suicidal thoughts or emotional disturbances. In a study conducted in Canada, the use of propoxyphene along with drugs like Neurontin led to risk of hip fracture in the elderly people. It also increased the risk of extended usage of sedatives and anti-depressants, possibly due to the impairment of the psychomotor functions. These drugs when used in combination could be very dangerous. In the kinetics of the medicine, propoxyphene increases the plasma concentrations of psychotropic agents which is not preferred. Therefore, usage of this Neurontin with propoxyphene based drug has to be restricted or reduced, especially in the elderly class and people with existing emotional disturbances.

Simultaneous use of levomethadyl acetate (Orlaam - drug for opiate addiction Ed.) and Neurontin can have very serious consequences in the Central Nervous System. This combination results in the respiratory depression and reduced heart rates. It can also lead to coma and sedation. Also, consumption of alcohol while taking Neurontin needs to be strictly restricted to prevent any damage to the Central Nervous System. Consumption of alcohol may tend to increase the symptoms like dizziness, co-ordination problems and confusion. The side effects of Neurontin are increased when alcohol is taken concurrently. It may not be possible for you to consume as much alcohol as you were used to. Alcohol and Neurontin in elderly people makes a bad combination. The side effects are much pronounced in them. If you are still persistent in taking alcohol, make sure that your body is not experiencing any side effects. It is also suggested that the usage of sodium oxybate needs to be avoided while consuming Neurontin for the same purpose as mentioned above. Naproxen is a medicine used to combat pain related to bone, inflammation, tendon injury etc. As with any pain killer, Naproxen also works by controlling the pain signals to and from the brain. So, this also needs to be carefully used with Neurontin.

Antacids influence the functioning of the Neurontin. They reduce the availability of Neurontin almost by twenty percent. This can be very dangerous as it reduces the protection offered by Neurontin to people suffering from epilepsy. For this reason, it is advised that Neurontin must be consumed at least two hours before taking any antacids. If morphine is administered along with Neurontin, it increases the serum levels of Neurontin. It is recommended to avoid herbal medicines during Neurontin usage. Primerose, an herbal component has the ability to keep away the threshold of seizure. Hence it is advised to avoid any herbal medicine that includes this component. Also it is recommended to avoid intake of herbal drugs that contain valerian or gotu kola. These components increase the depression of the Central Nervous System. So, it is advised that all the drugs influencing Central Nervous System must be used carefully with Neurontin.

http://www.neurontin-gabapentin.com/neurontininteractions.html

Tuesday, August 1, 2017

The Importance of Drug Development for Neuropathy


As time goes on and we survive longer, we tend to forget how destructive HIV has been and still is.

Today's post, is another powerfully written, personal account which speaks to everyone who has come into contact with HIV. It reminds us all where we've come from and how some have had easier journeys than others; something which does no harm at all every now and then but it also reinforces the need for more research and development when it comes to drugs to help treat both HIV and neuropathy. Ironically, the advance in HIV drug treatments has inadvertently meant an increase in neuropathy cases amongst HIV patients, if only because people are living much longer and being more frequently confronted with 'by-product' diseases. Neuropathy treatment itself however, is not making significant progress despite the ironically added bonus of having significant other patient groups involved (diabetes, cancer etc) and research into treatment for nerve damage, needs the same impulse that is consistently given to HIV medications!



HARRT Benefits - HIV/AIDS drugs saved my life!!
by Bradford McIntyre

From the time I was told I had “six months to live” by an AIDS specialist in 1985, I learned from other people infected with HIV and included supplements and complementary therapies. These kept me healthy and were responsible for allowing me to address health issues, boost my immune system and avoid going on HIV/AIDS medications for over a dozen years.

It was not that I did not get sick or need medical attention throughout the years, because I certainly did. There were countless doctors’ appointments, blood tests at the hospital to keep watch on how my body was reacting to having the virus and more times than I can count trying to fix whatever complications appeared. Throughout these years, large numbers of infected individuals went from a weakened immune system, to no immune system, to one sickness after another. With the advent of newer and better HIV/AIDS medications and a much broader understanding of this illness, individuals have been able to bounce back and have wellness restored with the aid of combination therapies. Equally, throughout everything, sick or well, complementary therapies are a mainstay to address: diarrhoea, nausea, neuropathy, irritated skin and rashes, wasting, fatigue, loss of appetite, immune-suppression and more, when it comes to living with HIV. We have learned a much broader understanding of this illness!

After approximately 13 years since diagnosis of infection with HIV, I did become seriously ill. In July of 1998, I developed pneumocystis-carinii-pneumonia, known as PCP. My health deteriorated and it looked as though I might die. My only recourse was to try an HIV/AIDS drug combination to boost my compromised immune system enough to fight off the pneumonia. That is exactly what happened. On December 1st, World AIDS DAY, 1998, I started my first ever HIV/AIDS drug combination treatment.

After just four weeks on the medication, my cd4 count of 40 went up a couple hundred points; eradicated the PCP and the viral load of several millions viral particles went down to thousands. With a reduced viral load, I could once again absorb nutrients. I regained the weight lost and started to strengthen my body through nutrition, exercise and complementary therapies.

People who knew me were very surprised that I started HIV/AIDS medications. They knew I was very involved in addressing HIV infection through alternative and complementary therapies. Although I was fortunate to have lived 13 years without highly active antiretroviral therapies (HARRT), I was not opposed to them. I was very successful addressing my health concerns without them, but I was aware of the benefits of pharmaceutical treatments and kept myself well informed. I knew there was a possibility of having to go on them one day. It was my hope that I could maintain good health without them, or by the time I needed them that they would be much improved from the drugs used in earlier years. It worked out for me in the long run. Without the drug combination therapy, I would not have survived. They saved my life!

Without the availability of these drugs, there would be far more suffering and deaths. Some individuals do not tolerate these medications, as they can be toxic. This is true of the treatments for many people who live with cancer and other illness, but you do not see activists denouncing the use of these life saving drugs. Myself and countless others have gone on to enjoy life, aided by these medications and it is very important to recognize the enormous benefits from the treatments available.

After two years, my HIV/AIDS drug combination began to fail. A genome test showed I was resistant to all the HIV/AIDS medications, even though my only usage consisted of AZT for 9 months (years earlier) and the current drug treatment. In 2000, with resistance to all existing HIV/AIDS medications, I enrolled in a drug study for a new protease inhibitor, Kaletra. Within the first four weeks on the drug my cd4 count climbed to 340 and my viral load was undetectable (less than 50 particles). In 2001, Kaletra was approved for use. Here it is 2004, and I am still taking Kaletra and I have a cd4 count of 470 and the virus is undetectable.

I recognize the significant accomplishments of science, medicine and the pharmaceutical companies and commend the work being done. Many are benefiting and I have seen people who were seriously ill regain a quality of health due to the HIV/AIDS treatments, myself included! I have seen people who were at one time in wheelchairs, recover and return to wellness due to new drug treatments and protease inhibitors. Weight gain, energy and hope have been restored in what might otherwise have meant death without these drugs. Initially, people did not have the treatment options we have today, but they led the way. Many people died in the process.

People offered themselves to science in the hope of finding a way to stay well, stay alive and move forward in treatment options. Without individuals engaged in studies and drug trials, we would not have the success in saving lives we have today. Many benefit and live longer due to the new drug treatments and protease inhibitors available. Obviously, we are moving forward in the development of more effective drug treatments!

Bradford McIntyre, HIV+ since 1984
Vancouver, B.C.
http://www.positivelypositive.ca/articles/harrt.html


Suspect Drug Interactions for HIV and Neuropathy Patients


Today's post from Aidsmeds.com (see link below) concerns the somewhat controversial view that older anti-seizure drugs can clash with HIV anti retroviral drugs to such a degree that the HIV meds can fail, with all the ensuing consequences. Underneath the article are comments which dispute that view but for HIV-patients who take Carbamazepine amongst others, in combination with Prezista amongst others, for their neuropathy problems, this is a very important question which needs to be resolved. Your neurologist and/or hiv-specialist may not be aware of the potential clash between the drugs so you should certainly discuss the issue with them perhaps with a photocopy of this article to back up your concerns. The article explains why the clash occurs.

Certain Anti-Seizure Drugs Up the Risk of HIV Treatment Failure
June 14, 2011

People taking older anti-seizure medications that are broken down by the same liver enzyme (CYP3A4) as many common antiretroviral (ARV) drugs were more likely to experience treatment failure than people taking seizure medications that aren’t broken down by that liver enzyme. These data were published online May 16 in the journal AIDS Research and Therapy.

A significant minority of people with HIV use anti-seizure medications. Roughly 11 percent of all HIV-positive individuals are diagnosed with a seizure disorder, and a substantial number of additional people use the same class of drugs for other disorders, including neuropathic pain, bipolar disorder and depression.

Though FDA guidelines recommend against combining—or urge caution when combining—some of the older anti-seizure drugs with ARV therapy, not all people have the option of the newer medications. For some people this is because the new medications don’t control their seizure disorders well, or because they can’t tolerate the newer drugs. The lack of available alternative drugs in resource-poor settings is another common reason why people with HIV still use them.

The problem with these older anti-seizure drugs is that they are broken down by the liver enzyme CYP3A4. This enzyme is also required to break down protease inhibitors such as Prezista (darunavir) as well as non-nucleoside reverse transcriptase inhibitors such as Sustiva (efavirenz) and the entry inhibitor Selzentry (maraviroc). This means that people who combine the anti-seizure drugs with their HIV therapy might be at higher risk of HIV treatment failure.

To study how a group of older anti-seizure drugs—including Dilantin (phenytoin), Tegretol (carbamazepine) and Luminal (Phenobarbital)—affects ARV treatment, Jason Okulicz, MD, from the Uniformed Services University of the Health Sciences in Bethesda, Maryland, and his colleagues studied the medical records of a group of HIV-positive people enrolled in the U.S. Military HIV Natural History Study.

Okulicz and his colleagues compared the rates of treatment success in 19 HIV-positive people taking the older anti-seizure drugs, with 85 people taking new anti-seizure drugs and 190 people taking no seizure medication. The research team only included people taking anti-seizure medication for either a seizure disorder or neuropathy.

The groups were similar in most respects, except that those taking the older anti-seizure medications were more likely to have a seizure disorder and those taking the newer medications were more likely to have neuropathy. The criteria for a person to be defined as having treatment failure included having no viral load measures under 400 copies within the first six months after starting ARV therapy, or having at least two measurements above 400 copies after the first six months of therapy.

Okulicz’s team found that treatment failure was more than four and a half times more common in people taking the older anti-seizure medication. This difference held up even when the team accounted for differences in viral load before starting therapy and the year in which people started therapy. The difference between people on the older anti-seizure drugs and those taking no anti-seizure medication was less meaningful, however. People on the older anti-seizure medications were only significantly more likely to experience treatment failure than those taking no anti-seizure medication when pre-treatment viral loads were taken into account.

“[Older anti-seizure medications] should be avoided in favor of [newer medications] in patients requiring concurrent [ARV treatment] and [anti-seizure] therapy due to the higher potential of virologic failure and reduced efficacy,” conclude the authors, who added, “In areas where [older anti-seizure medication] use cannot be avoided, closer and more frequent monitoring of HIV and seizure control is warranted.”
Previous Comments:
comments 1 - 3 (of 3 total)

David Evans, AIDSmeds, New York, NY, 2011-06-23 15:55:37
While there was a difference in the risk of treatment failure between those on older versus newer anti-seizure meds, there was less difference between those NOT taking seizure meds and those taking older-seizure meds. The authors don't provide an explanation, but argue that there may have been more significant differences in terms of baseline viral load and and adherence between those on and off seizure meds compared with the two groups that were both taking seizure meds.

Steven McLaughlin, Washington, DC, 2011-06-17 12:55:25
This article is poorly written and provides no meaningful data. In the 8th paragraph the author states that the individuals taking the older seisure meds were 4.5X more likely to have treatment failure and then in went on to say,"The difference between people on the older anti-seizure drugs and those taking no anti-seizure medication was less meaningful, however." The author tried to identify patterns but did not clearly establish a causal relationship between the 3 groups of test subjects.

jjbearphx, Phoenix, 2011-06-16 11:37:22
I have HIV induced eplepsy. My experience is not failure to maintain viral suppression, but failure of the anti seizure meds Dilantin then Zonigram was added and that has causes exacerbation of neuropathy. Hideous AM Med Hang over, that doubles after my AM antiviral pass as liver dumps toxins to work on HIV meds. Anti Epileptics aren't covered on ADAP formularies end up o o pocket, new anti seiz drugs are expensive. Lack of access to epileptologists makes things harder all around. not covered


http://www.aidsmeds.com/articles/hiv_seizure_protease_1667_20615.shtml

Friday, July 28, 2017

ANTI EPILEPSY DRUG PRESERVES BRAIN FUNCTION AFTER STROKE


New research suggests that an already-approved drug could dramatically reduce the debilitating impact of strokes, which affect nearly a million Americans every year.
In the study, one dose of the anti-epilepsy drug, retigabine, preserved brain tissue in a mouse model of stroke and prevented the loss of balance control and motor coordination. Researchers from the School of Medicine at The University of Texas Health Science Center at San Antonio conducted the study, which was published Feb. 3 in The Journal of Neuroscience.
Balance and coordination test
Hours after a stroke, both treated mice and a control group of mice were placed on a balance beam to observe motor coordination. The untreated mice displayed a pronounced loss of coordination with slips and falls. Treated mice had no difficulty with balance, ambulation or turning around on the beam.
"You couldn't even tell they had a stroke," said senior author Mark S. Shapiro, Ph.D., professor of physiology at the UT Health Science Center San Antonio. "They ran across the balance beam like gymnasts."
Histological analysis of the brain tissue of treated mice showed significantly reduced damage to the tissue after the stroke, compared to untreated mice. The protective effects of the medication were observed in treated mice up to five days after the stroke, said Sonya Bierbower, Ph.D., postdoctoral fellow and lead author of the report.
Duration of effect
Future studies will assess how long brain function can be protected after a stroke, and whether injury-related seizures can be prevented. "We are also going to see if we can prevent strokes in high-risk animal models," Dr. Bierbower said.
Retigabine and similar agents open specific proteins called potassium ion channels, whose action stops the electrical activity of nerve cells in the brain. The San Antonio team studied ischemic stroke, in which oxygen and nutrients are suddenly cut off due to a clot in a blood vessel. This is the type of stroke most often seen in humans. "We thought if we could stop the neurons from firing, stopping their electrical activity, we could conserve their resources until the time their blood supply was restored," Dr. Shapiro said. "This proved to be the case."
Cells starved of oxygen and nutrients for six hours are compromised and the process of dying is nearly impossible to reverse. Moreover, when cells die, they release factors that trigger many types of responses including an inflammatory response, leading to more cell death in the areas around the blood clot.
tPA for clots
A drug called tissue plasminogen activator (tPA) treats stroke by dissolving clots to restore blood flow, but this has significant limitations. tPA causes severe thinning of the blood, so it is not an option for patients who have high blood pressure, a history of bleeding or weak blood vessels. tPA is most effective in the first hours after a stroke, but its later use may do more damage than good.
Directly affecting nerve cells
Potassium channel openers such as retigabine work on a completely different system. "They have nothing to do with thinning blood, but preserving cells by putting a brake on their electrical activity," Dr. Shapiro said.
"It's treating the first step in the sequence and stopping the more damaging secondary effects," Dr. Bierbower said. "These agents directly affect the nerve cells themselves."
FDA approved for epilepsy
Because retigabine is approved by the U.S. Food and Drug Administration under the American brand name Ezogabine as an anticonvulsant, physicians may use it off label in stroke patients. FDA approval for specifically this drug as stroke therapy will require a clinical trial to be conducted, and a team of neurologists and neurosurgeons at the Health Science Center is considering it, Dr. Shapiro said.
"As a leading cause of death and disability, stroke poses a major risk to our society," said David F. Jimenez, M.D., FACS, professor and chairman of the Department of Neurosurgery at the Health Science Center. "It is very exciting to see that our collaborative work with our colleagues in physiology could provide a superb way to ameliorate the harmful effects of stroke on our patients."


Monday, July 24, 2017

Combination Drug Therapy For Neuropathy Pain


Today's post from painnewsnetwork.org (see link below) reinforces an article from last week on the blog concerning using a combination drug therapy to better relieve neuropathic pain. It talks about two drugs (the anti-depressant, nortryptiline and morphine) which are currently two of the individual treatments in the range of drugs used to suppress neuropathic symptoms. Using them in combination seems to work more effectively than single drug treatment according to UK researchers. They are also relatively cheap (important in today's climate) but do carry the risk of side effects and that needs to be discussed and monitored by your doctor. Apart from that, the nature of neuropathy is that patients react so differently to different drug treatments - there's no one drug which doctors can truthfully say works for all. So it's entirely possible that this combination will not work for you, just the same as the individual drugs may not work for you. That said, the idea of combining drugs with carefully controlled and safe dosages, seems logical on all points but if your doctor suggests this to you, make sure you discuss all possible outcomes and ensure that he or she will monitor the situation very carefully - these drugs are not M&Ms. One final point, some doctors prescribe morphine and the anti-convulsant, gabapentin (neurontin) combinations too.

Two Drug Combo Relieves Neuropathy PainBy Pat Anson, Editor April 08, 2015

British researchers say a combination of two widely used drugs – an antidepressant and an opioid – can significantly relieve pain and other symptoms caused by neuropathy.

In a study published in the journal PAIN, researchers at Queens University say combining the painkiller morphine with the antidepressant nortriptyline relieved chronic neuropathic pain in nearly 90 percent of patients – significantly better than when either drug is used alone.

"Morphine and nortriptyline are excellent candidates for pain management because of the extensive research conducted on them, their low cost, and widespread availability all over the world," said Ian Gilron, MD, a professor in Queen's School of Medicine and anesthesiologist at Kingston General Hospital.

"Current neuropathic pain treatments are ineffective or intolerable for many sufferers so this new evidence supporting the morphine-nortriptyline combination is important news for patients."

Nortriptyline, an antidepressant sold under the brand names Aventyl and Pamelor, is already being used to treat pain in the arms and legs caused by multiple sclerosis. Morphine has long been used to treat both acute and chronic pain.

Neuropathic pain is characterized by tingling or burning sensations that develop as result of nerve damage caused by conditions such as shingles, diabetes, amputation, inflammation, and cancer. About 8% of adults worldwide suffer from neuropathy. Many drugs used to treat neuropathic pain, such as Neurontin and Lyrica, often don’t work or have unpleasant side effects.

In the double-blind, randomized study, 52 neuropathy patients were given a choice of trying every one of three treatments: morphine alone, nortriptyline alone, and a combination of the two drugs over six-week treatment periods. Patients were asked to record their pain levels and side effects during each treatment.

The average daily pain before treatment was 5.6, measured using a rating scale from 0-10. Average daily pain dropped to 2.6 when patients received the two drug combination. Patients taking nortriptyline and morphine alone rated their pain at 3.1 and 3.4, respectively.

Researchers said that common side effects for both drugs, which include constipation and dry mouth, did not worsen with the combined treatment.

"It's important to remember that we don't want to completely eliminate patients' ability to sense pain as it's a warning system for us, but we do want to find the right balance of pain relief and drug side effects," said Gilron

Nortriptyline and morphine are currently not available in a combined formulation. According to the Mayo Clinic, using the two drugs together is usually not recommended because they both cause sedation.

http://www.painnewsnetwork.org/stories/2015/4/8/two-drug-combo-relieves-neuropathy-pain


Wednesday, July 12, 2017

Prescription Drug Misuse Declining Or Not


Today's post from pain-topics.org (see link below) follows on from yesterday's post in that it looks at the results of prescription drug availability and abuse. It seems, according to the report, that non-medical drug abuse has and is falling in the USA while prescription drug abuse is clearly rising. The report highlights medical drug abuse as being a big problem for now and the future but as Dr Leavitt's commentary below suggests, it may not be as cut and dried as it seems. Either way, as neuropathy patients who are on opioid and opium family drugs well know, the potential for addiction is always there and patients need to be carefully and regularly monitored by their doctors, to try to minimize the risk.



Rx Pain Reliever Misuse Declining?
Posted by SB. Leavitt, MA, PhD: Thursday, January 10, 2013

A new United States government report shows that prescription drug misuse decreased in 10 states between 2009 and 2011, and did not increase in any other states during that time. Yet, the government seems unimpressed by these results, and there could be biases in the reporting that are distorting the evidence to make the problems loom larger than reality as well as overlooking underlying causes.

The report issued by the U.S. Substance Abuse and Mental Health Services Administration (SAMHSA) on January 8, 2013 [available here] notes that 22 million people used prescription pain-relieving drugs for “nonmedical purposes” since 2002. And, such Rx-drug misuse is just behind marijuana as the country’s most widespread drug problem, according to SAMHSA.

At the same time, however, the report states that comparisons of combined 2009-2010 data with combined 2010-2011 data show that past year nonmedical use of prescription pain relievers among persons aged 12 or older decreased in 10 states (Kentucky, Louisiana, Massachusetts, Mississippi, New Hampshire, New York, Ohio, Oklahoma, Rhode Island, and West Virginia), and leveled-off during that timeframe in all other states on average.

Iowa had the lowest rate of nonmedical prescription drug use, at 3.6%, while Oregon had the highest rate — 6.4%. Seven of the 10 states with the highest levels of prescription analgesic misuse were in the West: ie, Washington, Oregon, Nevada, New Mexico, Idaho, Colorado, and Arizona. Two other high ranking states were in the South (Arkansas and Delaware), and one was in the Midwest (Indiana).

The national rate for the overall U.S. population declined between 2009-2010 and 2010-2011 — from 4.9% to 4.6%. The rates also decreased nationally during those time periods among persons aged 12 to 25, but remained unchanged overall among persons aged 26 or older. This older group already had analgesic misuse rates significantly lower than teenagers and young adults, but even among older persons there were declines in many states.

Data for the report were from the National Survey on Drug Use and Health (NSDUH), which asks persons aged 12 or older questions related to their nonmedical use of prescription pain relievers during the past year. Such “nonmedical use” is defined as (a) use of the analgesics without a prescription, or (b) use that occurred simply for the experience or feeling the drug caused; over-the-counter (OTC) drug use and legitimate use of prescription analgesics are not included.

In a news release [here], Pamela S. Hyde, SAMHSA Administrator, stated…

“Addressing prescription drug misuse remains a top public health priority, as we’ve seen inconsistent progress in addressing the issue across the states. Data from this report helps us better understand geographic variations in use, and should help with the development of more targeted and effective prevention and treatment programs. The key is educating the public on the serious health risks involved, and ensuring that we are providing the necessary treatment to those who need it.”

COMMENTARY: This report is significant news, since nonmedical use has declined even as the rate of analgesic prescribing overall has been increasing. Yet, the government often appears to emphasize the negative side of such data in continuing to portray an “epidemic” of prescription drug misuse, rather than lauding the remarkable progress that has been made.

Importantly, definition of the problem may be contributing to misperceptions that inflate the data. “Nonmedical use” of prescription analgesics is conflated with abuse, and includes using the drugs either for recreational purposes to get “high”OR using the drugs as intended for pain, but without appropriate authorization — a form of “medical misuse.”

In other words, someone who once “borrowed” a prescription pain reliever from a relative or friend for a toothache, and answered honestly on the NSDUH survey, would be categorized as a nonmedical user (abuser). This is the same category as someone who stole prescription pain pills from their parents’ medicine cabinet to get high at a party. Yet, the motivations are strikingly different, even though both uses could be quite hazardous, and solutions to the respective problems also would be very different.

For example, some time ago in an UPDATE article [here] we reported on a large survey of high school seniors that found 12.3% of them used opioid analgesics for “nonmedical” reasons at some time. Yet, on closer inspection, 45% of the “misusers” actually took the drugs for self-medicating physical pain. This was similar to other studies finding that roughly half of so-called “nonmedical use” among students was to relieve pain; albeit, such use was unauthorized due to the person not having a prescription of their own.

As we noted in that earlier UPDATE, an important public health question might be, “Why are so many young persons suffering from untreated (or mistreated) physical pain, causing them to seek remedies on their own?” Perhaps, it is more convenient for them to borrow a few pills from a friend than go to a healthcare provider. Or, are there access-to-care and undertreatment of pain problems among these youngsters that need to be addressed?

It is interesting to observe in the latest SAMHSA data that the group with the highest rates of analgesic misuse are young adults 18-to-25 years old. Surely, this is an active time of life that may be filled with sports injuries and acute physical aches/pains of various types, as well as a period of experimentation with many life experiences — including drugs. Although the data do show some significant declines in drug misuse in this age group, as in the other groups, these young persons might represent a special target for prevention and education efforts.

Meanwhile, in older persons, with the lowest rates of “nonmedical” analgesic use in the SAMHSA data, one might speculate that such misuse more often than not is for the unauthorized self-treatment of pain. Furthermore, the use of marijuana among older age groups could be more often for pain than purely recreational use. We need better ways of capturing and categorizing such data, and then addressing the true underlying problems; although, the government has not shown any interest in doing this in the past. What do readers think?

http://updates.pain-topics.org/2013/01/rx-pain-reliever-misuse-declining.html

Sunday, July 2, 2017

Which Drug Companies are Investing in Neuropathy


Firstly , sincere apologies for yet another scientifically complex post that is difficult to understand. However, gathering information is important for us all; it helps us build up a picture of how treatment of our disease is being handled and being developed for the future. The fact that, if you're like me, you gloss over the difficult bits and only remember the things that stick, is not so important because you get a rough idea of what's happening, even if you only understand a quarter of it. Today's article from Innovaro pharmalicensing (see link below) gives an update on which drug companies are actively researching and developing new and effective ways of treating neuropathic pain. We've stamped our feet pretty quietly up to now and shouted without really being heard, that what we have is a largely ignored disease (for all sorts of reasons) but now the huge conglomerates seem to have finally decided there is money to be made by coming up with a successful drug treatment. We can only hope that they're successful and that it doesn't take too long!

Novel Treatments in the Pipeline for Neuropathic Pain
By Gail Schechter, Ph.D.

Characterized by sensations of burning, numbness, and tingling, neuropathic pain is debilitating and difficult to treat; it afflicts more than 5 million persons in the U.S., most patients are unsuccessfully treated, and the cost in lost productivity exceeds $100 billion annually.

Neuropathic pain has multiple etiologies, including metabolic disease, infectious disease, mechanical trauma, central nervous system disorders, toxic agents, compression injuries, and malignant conditions. Specific conditions commonly associated with neuropathic pain include: diabetes, postherpetic neuralgia (shingles), HIV/AIDS, cancer/chemotherapy, alcoholism, trigeminal neuralgia (tic douloreux), fibromyalgia, complex regional pain syndrome, phantom limb pain, carpal tunnel syndrome, back pain, multiple sclerosis, spinal cord injury, and stroke.

For most of the past 20 years, pharmacological treatment has depended primarily on a handful of medications, including old-fashioned tricyclic antidepressants, topical lidocaine and capsaicin patches, narcotics such as oxycontin, the painkiller tramadol, and the widely prescribed gabapentin (Neurontin), originally developed as an anti-seizure medication that modulates calcium influx and GABA transmission.

Big Pharma Provides Pain Relief
Pfizer has turned gabapentin into a $3 billion per year blockbuster medication (not without some bumps) and has recently launched its follow-on medication, pregabalin (Lyrica), fondly known as "super Neurontin." Studies indicate a superior therapeutic index for pregabalin compared to gabapentin. Launched in 2004 in Europe and the U.S., pregabalin was approved by the FDA to treat neuropathic pain associated with diabetic peripheral neuropathy and post-herpetic neuropathy, as well as adjunct treatment for partial seizures. In addition to the analgesic and anticonvulsant indications, it is likely that an anxiolytic indication will be approved in the near future.

Lilly's duloxetine (Cymbalta) also was launched in 2004. As a member of the new generation of antidepressants, duloxetine is a combined serotonin and norepinephrine reuptake inhibitor (SNRi). In addition to its approved indication for depression, it received an additional indication for pain management of neuropathic pain associated with diabetic peripheral neuropathy.

Emerging Therapeutic Targets for Neuropathic Pain
The recent BIO Emerging Company Investor Forum in San Francisco in October showcased more than 200 promising new companies, and it was clear that pain was a burning topic. Company presentations underscored major themes in current pain therapeutics, including: re-emergence of the N-methyl-D-aspartate (NMDA) receptor complex as a suspect of interest; NMDA receptor subtype-specific targets; increased understanding of physiological mechanisms of action; improved drug side effects profiles; better animal models to transition from preclinical to clinical studies; enhanced therapeutic index in humans; emphasis on oral formulations; and novel delivery techniques. Highlights from selected companies focused on pain, mainly neuropathic, illustrate the range of treatment candidates working their way through the pain pipeline.

New Tricks for Old Drugs
A resurgence of interest in NMDA receptors is evident in current pain research. New and improved versions of NMDA receptor antagonists, receptor subtype targets such as gycine, and ion channel modulators have been revived and refined.

Anavir Pharmaceuticals
Anavir focuses on the NMDA receptor as a prime target for the control of neuropathic pain. Excessive activation of the NMDA receptor has been implicated in many diseases, and pharmacological agents that attenuate NMDA receptor activity have been shown to be neuroprotective.

Anavir is developing Neurodex, dextromethorphan in combination with an enzyme inhibitor to block the rapid metabolism of dextromethorphan and maintain elevated blood levels. The rationale for using dextromethorphan to treat neuropathic pain is that it is a potent antagonist of the NMDA receptor. The use of low dose quindine sulfate, an established medication for cardiac arrhythmia, blocks enzyme activity responsible for the rapid degradation of dextromethorphan and sustains elevated blood levels thought to be effective in treating neurological disorders.

Neurodex currently is being tested for the indication of neuropathic pain. Avanir has completed a Phase II trial in patients with diabetic neuropathy. Treatment was well-tolerated and significantly decreased pain intensity. Avanir currently is discussing the Phase III protocol with FDA. Neurodex is also in Phase III clinical trials for uncontrolled laughter or tearfulness, called pseudobulbar affect, occurring in patients with amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's disease, and stroke.

GB Therapeutics Ltd.
GB Therapeutics is targeting the NMDA glutamate receptor recognized for its role in pain and memory. The glutamate antagonist GT 3381 licensed from Chiesi showed good pain relief and a superior safety profile in humans.

Touted as the first new treatment in the third-generation oral NMDA modulators, GT 3381 currently is in Phase II clinical trials as a first-line therapy for neuropathic pain. The company also is developing GT 1061 as a neuroprotective agent to slow the progression of memory and cognitive deficits in Alzheimer's disease.

VistaGen Therapeutics, Inc.
VistaGen is developing a drug targeting epilepsy and neuropathic pain. VistaGen's lead drug candidate AV-101 is an NMDA receptor antagonist entering clinical development. This drug addresses the limitations of previous NMDA receptor antagonists by providing a high therapeutic index, i.e., potent efficacy and minimal adverse side effects. AV-101, L-4-chlorokynurenine, is a novel orally available prodrug (7-chlorokynurenic acid) that is preferentially converted to a potent glycine receptor antagonist at the site of neural damage, where it protects neurons from excitotoxic cell death. The company expects to initiate its AV-101 clinical program for epilepsy and neuropathic pain in early 2006.

The company's second drug candidate, AV-102, modulates neural pathways essential for memory and cognitive function and has therapeutic applications for mental decline associated with disorders of aging. The company also has a unique drug discovery program based on the use of clinically predictive in vitro embryonic stem cells to identify a new generation of drug candidates to treat central nervous system disorders.

Evotec Neurosciences GmbH
Evotec is developing an NMDA receptor NR2B subtype selective antagonist as a neuroprotective agent for neuropathic pain and central nervous system disorders including Parkinson's disease, Alzheimer's disease, stroke, and traumatic brain injury. Previous efforts to develop less selective NMDA antagonists have been plagued by a narrow therapeutic index and delicate balance between clinical benefits and side effects.

The NR2B receptor is forebrain specific and appears to have an improved side effect profile and wider therapeutic index. Its oral availability and lack of off-target responses show promise in animal models. As the company's lead compound, it is anticipated that it will enter into Phase I clinical trials in mid-2005.

Neuromed Technologies, Inc.
Neuromed is the only company in the world with a sole focus on developing calcium channel drugs. Using proprietary screening systems, Neuromed has identified a selective N-type calcium channel blocker with analgesic effects on severe chronic pain. Proof-of-principle for pursuing a peptide that blocks the N-type calcium channel is based on the drug ziconotide (Prialt) that effectively treats severe chronic pain but must be administered intrathecally (directly into the fluid surrounding the spinal cord through a surgically implanted catheter). Ziconotide, a synthetic equivalent of a naturally occurring conopeptide found in a marine snail known as Conus magus, selectively blocks calcium channels on the nerves that ordinarily transmit pain signals to the brain.

Of great importance is the oral and intravenous bioavailability of Neuromed's small molecule drug and its potential to deliver pain relief with minimal side effects. The company's lead candidate drug for chronic pain, NMED-160, is in a Phase I double-blind, randomized, placebo-controlled clinical trial designed to evaluate the drug's safety, tolerability, and pharmacokinetics in healthy individuals. Neuromed also has pipeline programs in anxiety, epilepsy, and cardiovascular disease.

International WEX Technologies, Inc.
Wex's lead product is Tectin for the initial indication of cancer pain and possibly other broad pain indications in the future. The sodium channel blocker, which acts to block pain signals, is derived from the pufferfish toxin, tetrodotoxin (TTX).

Phase II clinical trial results demonstrated that Tectin could relieve pain in refractory cancer pain patients. A recently initiated pivotal Phase IIb/III trial in 25 treatment centers is a randomized, placebo-controlled study in patients with moderate-to-severe cancer pain that is inadequately controlled by existing medication. Tectin is administered via intramuscular injection. The study results are expected in 2005.

ACADIA Pharmaceuticals
ACADIA is developing a class of small molecule agents that activate G-protein coupled receptors (GPCRs) implicated in pain. The two new receptor targets, NPFF and MrG, play a pharmacologically relevant role in pain signaling. The GCPRs appear to have potent, subtype-selective activity. The chemistries were initially found through ACADIA's chemical-genomics technology in which the company is systemically screening members of the GPCR family.

The new targets for pain expand the drug discovery efforts in pain therapeutics, including ACP-102 that targets a GPCR receptor and a preclinical development program targeting muscarinic receptors. The company is in clinical trials for ACP-103 and ACP-104 as adjunctive treatment of schizophrenia and Parkinson's disease.

Pain Therapeutics, Inc.
Pain Therapeutics is developing Oxytrex to treat severe chronic pain. Oxytrex is a unique oral painkiller that combines oxycodone plus ultra low-dose naltrexone to preferentially inhibit an excitatory effect of opioid receptors. This excitatory effect is believed to counteract analgesia and cause tolerance. Its inhibition enhances pain relief and minimizes opioid tolerance.

The company currently is conducting pivotal studies in patients with severe chronic low-back pain (first Phase III) and osteoarthritic pain (second Phase III) to compare the safety and efficacy of Oxytrex against the same total daily dose of oxycodone or placebo. Future research will be directed at the indication of neuropathic pain.

Pharmos
Pharmos' chemical library and list of lead preclinical drug candidates comprise two chemically distinct cannabinoid platforms, the dextrocannabinoid class of compounds and a separate class of cannabinoids showing selectivity toward CB2 receptor binding (PRS 375). Pharmos has completed preclinical/toxicological testing and is ready to move into clinical studies with PRS 375 for pain.

Currently, Pharmos is focusing its resources on its first neuroprotective product, dexanabinol, a non-psychotropic dextrocannabinoid currently undergoing Phase III clinical trials as a treatment for traumatic brain injury and Phase II testing as a preventative agent against post-surgical (CABG) cognitive impairment.

Dov Pharmaceuticals, Inc.
Dov's lead candidate is bicifadine, a chemically distinct molecule with a unique profile of pharmacological activity. It enhances and prolongs the actions of serotonin and norepinephrine by inhibiting the transport proteins that terminate their physiological actions, similar to the mechanism of action of duloxetine. Preclinical studies and clinical trials indicate that these actions may account for the analgesic properties of bicifadine in chronic pain conditions including neuropathic pain.

To date, bicifadine has been tested in 1,555 patients in a number of Phase I and II clinical trials using both immediate- and controlled-release formulations. Bicifadine demonstrated a statistically significant reduction in pain, in some cases comparable to or better than positive controls such as codeine. Phase III clinical trials are planned soon.

XenoPort, Inc.
XenoPort is focused on developing products that harness the body's intrinsic transport systems to improve the oral absorption, distribution, and pharmacokinetics of drugs. The company applies an integrated technology platform--consisting of transporter genomics, assay technology, and proprietary chemistries--to engineer drug molecules for active transport. XenoPort currently is applying its technology to off-patent drugs to provide new, patentable compounds with improved medicinal properties.

XenoPort is in the process of creating new patentable Transported Prodrugs. The company recently initiated two Phase II clinical trials with XB13512, XenoPort's proprietary experimental Transported Prodrug of gabapentin, as a potential treatment for post-herpetic neuralgia and restless legs syndrome.

AlgoRx
AlgoRx is focused on building a diversified portfolio of pharmaceutical products to treat pain. ALGRX 4975 is an injectable capsaicin product for localized, severe, intractable pain. A single administration is expected to provide analgesia for up to several months. Because ALGRX 4975 is injected directly into the painful tissue, it is anticipated to have much greater efficacy than low dose topical capsaicin that is currently available. Alternatively, during surgical procedures, it may be instilled into the surgical wound or onto the cut surfaces of skin, muscle, or bone. The company is pursuing multiple indications for ALGRX 4975: musculoskeletal pain (including osteoarthritis of the knee and tendonitis); post-surgical pain; and post-trauma neuropathic pain. ALGRX 4975 is currently in Phase II clinical development.

A second product in development is ALGRX 3268 (PowderJect(R) Dermal Lidocaine), a needle free, local dermal anesthetic providing analgesia within one minute. It is currently in Phase II clinical testing in children to reduce the pain associated with needlesticks for venipuncture or intravenous cannulations.

NeurogesX, Inc.
NeurogesX is taking a topical approach to treating neuropathic pain of peripheral origin. The company is developing a localized, high-concentration capsaicin dermal patch. The local anesthetic effect results from activation of the transient receptor potential vanilloid 1 (TRPV1) receptor (formerly vanilloid receptor 1 or VR1), a ligand-gated ion channel activated by agonists such as capsaicin. When capsaicin activates TRPV1, calcium enters the cell and pain signals are initiated. When TRPV1 is continuously activated through prolonged exposure to an agonist, excessive calcium enters the cell, initiating processes that result in long-term yet reversible impairment of nociceptor function. This is the proposed mechanism by which NGX-4010 delivers long-term relief to patients with neuropathic pain.

The lead candidate, NGX-4010, provides application of a pure, high-concentration form of synthetic capsaicin, known as trans-capsaicin, directly to the site of pain via a rapid-delivery dermal application system. This potential product is currently being studied in Phase III trials in postherpetic neuralgia and neuropathic pain related to HIV-associated neuropathy. Phase II trials are also ongoing for patients with neuropathic pain related to peripheral diabetic neuropathy.

Future Opportunities
Neuropathic and other chronic pain treatments still face formidable challenges. Increased efficacy, safety, onset of action, and continual day/night relief are desired, but as yet unattained, properties. It is likely that we will next see "me too" drugs following in the large footsteps of the anticonvulsants and antidepressants. The emerging compounds in the pipeline are innovative therapeutic candidates, but they still have a long way to go, and it is too early to predict their future.

http://pharmalicensing.com/public/articles/view/1101203436_41a307ec2804b